Glatiramer acetate for the treatment of multiple sclerosis

Bibliography

• DHIB-JALBUT S: Glatiramer acetate (Copaxone®) therapy for multiple sclerosis. Pharmacol Ther. (2003) 98:245–255.
   PubMed Web of Science ®Google Scholar
• LUBLIN FD, BAIER M, CUTTER G: Effect of relapses on development of residual deficit in multiple sclerosis. Neurology(2003) 61:1528–1532.
   PubMed Web of Science ®Google Scholar
• BJARTMAR C, FOX RJ: Pathological mechanisms and disease progression of multiple sclerosis: therapeutic implications. Drugs Today (2002) 38:17–29.
   PubMed Web of Science ®Google Scholar
• COMI G: Why treat early multiple sclerosis patients? Curt-. Opin. Neurol (2000) 13:235-240 (Editorial).
   Google Scholar
• GOODIN DS, ARNASON BG, COYLE PK, FROHMAN EM, PATY DW: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 61:1332–1338.
   PubMed Web of Science ®Google Scholar
• SELA M, TEITELBAUM D: Glatirameracetate in the treatment of multiple sclerosis. Expert Opin. Pharmacother: (2001) 2:1149–1165.
   PubMedGoogle Scholar
• TEITELBAUM D, MESHORER A, HIRSHFELD T et al.: Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur: j Immunol (1971) 1:242–248.
   PubMed Web of Science ®Google Scholar
• LISAK RP, ZWEIMAN B,BLANCHARD N, BORKE LB: Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). Neurol Sci. (1983) 62:281–293.
   Web of Science ®Google Scholar
• KEITH AB, ARNON R,TEITELBAUM D, CASPARY EA, WISNIEWSKI HM: The effect of Cop-1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J. Neurol Sci. (1979) 42:267–274.
   PubMed Web of Science ®Google Scholar
• FRIDKIS-HARELI M, NEVEU JM, ROBINSON RA et al: Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J. Immunol (1999) 162:4697–4704.
   PubMed Web of Science ®Google Scholar
• SMITH KJ, PYRDOL J, GAUTHIER L,WILEY DC, WUCHERPFENNIG KW: Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. (1998) 188:1511–1520.
   PubMed Web of Science ®Google Scholar
• AHARONI R, TEITELBAUM D, ARNON R, SELA M: Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. USA (1999) 96:634–639.
   PubMed Web of Science ®Google Scholar
• ARNON R, SELA M, TEITELBAUM D: New insights into the mechanism of action of copolymer 1 in experimental allergicencephalomyelitis and multiple sclerosis. Neurol (1996) 243\(Suppl. 1):58–513.
   Google Scholar
• NEUHAUS 0, FARINA C,WEKERLE H, HOHLFELD R: Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology (2001) 56:702–708.
   PubMed Web of Science ®Google Scholar
• CHEN M, GRAN B, COSTELLO K, JOHNSON K, MARTIN R, DHIB-JALBUT S: Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Malt. Scler: (2001) 7:209–219.
   Google Scholar
• MILLER A, SHAPIRO S, GERSHTEIN Set al.: Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Thl to Th2/Th3 immune-deviation. J. Neuroimmunol (1998) 92:113–21.
   Google Scholar
• DUDA PW, SCHMIED MC, COOK SL, KREIGER JL, HAFLER DA: Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.Clin. Invest. (2000) 105:967–976.
   Google Scholar
• •Suggests GA may be the first immunomodulatory treatment to suppress human autoimmune disease and alter immune function by engaging the T-cell receptor.
   Google Scholar
• DHIB-JALBUT S, CHEN M, SAID A, ZHAN M, JOHNSON KP, MARTIN R: Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with Th2-biasedphenotype. Neuroimmunol. (2003) 140:163–171.
   PubMedGoogle Scholar
• DUDA PW, KRIEGER JI,SCHMIED MC, BALENTINE C, HAFLER DA: Human and murine CD4 T cell reactivity to a complex antigen: Recognition of the synthetic random polypeptide glatiramer acetate. Immunol. (2000) 165: 7300–7307.
   Web of Science ®Google Scholar
• BRENNER T, ARNON R, SELA A et al.: Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxonea.f. Neuroimmunol. (2001) 115:152–160.
   Google Scholar
• •Describes immune responses in a large group of patients from three different clinical trials.
   Google Scholar
• RIEKS M, HOFFMANN V, AKTAS 0 et al.: Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate. Eur: Neurol. (2003) 50:200–206.
   Google Scholar
• CHEN M, CONWAY K, JOHNSON KP, MARTIN R, DHIB-JALBUT S: Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. Neurological. Sci. (2002) 201:71–77.
   Web of Science ®Google Scholar
• AHARONI R, TEITELBAUM D, LEITNER 0, MESHORER A, SELA AM, ARNON R: Specific Th2 cells accumulate in the nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc. Nati Acad. Sci. USA (2000) 97:11472–11477.
   PubMed Web of Science ®Google Scholar
• BIERNACKI K, PRAT A, BLAIN M, ANTEL JP: Regulation of Thl and Th2 lymphocyte migration by human adult brain endothelial cells. Neuropathol. Exp. Neural. (2001) 60:1127–1136.
   PubMed Web of Science ®Google Scholar
• AHARONI R, KAYHAN B, EILAM R, ARNON R: Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Nati Acad. Sci. USA (2003) 100:14157–14162.
   PubMed Web of Science ®Google Scholar
• •GA promotes release of BDNF in the CNS, a potential mechanism of action.
   Google Scholar
• CHEN M, VALENZUELA M, DHIB-JALBUT S: Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. Neural. Sci. (2003) 215:37–44.
   PubMed Web of Science ®Google Scholar
• YONG VW: Differential mechanisms ofaction of interferon-I3 and glatiramer acetate in MS. Neurology(2002) 59:802–808.
   PubMed Web of Science ®Google Scholar
• MOALEM G, LEIBOWITZ-AMIT R, YOLES E, MOR F, COHEN IR, SCHWARTZ M: Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. (1999) 5:49–55.
   PubMed Web of Science ®Google Scholar
• KIPNIS J, YOLES E, PORAT Z et al.: T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies. Proc. Natl. Acad. Sri. USA (2000) 97:7446–7451.
   PubMed Web of Science ®Google Scholar
• SCHORI H, KIPNIS J, YOLES E et al.: Vaccination for protection of retinal ganglion cells against cell death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc. Nati Acad. Sci. USA (2001) 98:3398–3403.
   PubMed Web of Science ®Google Scholar
• GILGUN-SHERKI Y, PANET H, HOLDENGREBER V, MOSBERG-GALILI R, OFFEN D: Axonal damage is reduced following glatiramer acetate treatment in C57/61 mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci. Res. (2003) 47:201–207.
   PubMed Web of Science ®Google Scholar
• ANGELOV DN, WAIBEL S, GUNTINAS-LICHIUS 0 et al.: Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Nati Acad. Sci (2003) 100:4790–4795.
   Google Scholar
• KAYHAN B, AHARONI R, ARNON R: Glatiramer acetate (Copaxone®) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis. Immunol. Lett. (2003) 88:185–192.
   PubMed Web of Science ®Google Scholar
• PARKINSON JF, MITROVIC B, MERRILL JE: The role of nitric oxide in multiple sclerosis.' Moi Med. (1997) 75:174–186.
   PubMed Web of Science ®Google Scholar
• THOENEN H: Neurotrophins and neuronal plasticity. Science (1995) 270:593–598.
   PubMed Web of Science ®Google Scholar
• ZIEMSSEN T, KUMPFEL T,KLINKERT WEE NEUHAUS 0, HOHLFELD R: Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brant (2002) 125:2381–2391.
   PubMed Web of Science ®Google Scholar
• STADELMANN C,KERSCHENSTEINER M, MISGELD T, BRUCK W, HOHLFELD R, LASSMANN H: BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions betweenimmune and neuronal cells? Brain (2002) 125:75–85.
   PubMed Web of Science ®Google Scholar
• CHABOT S, YONG FP, LE DM, METZ LM, MYLES T, YONG VW: Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Malt. Scler. (2002) 8:299-306.39. TEITELBAUM D, AHARONI R,SELA M, ARNON R: Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc. Nati Acad. Sci. (1991) 88:9528–9532.
   Google Scholar
• URE DR, ROGRIGUEZ M: Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J. (2002) 16:1260–1262.
   PubMed Web of Science ®Google Scholar
• FARINA C, VARGAS V, HEYDARI N, KUMPFEL T, MEINL E, HOHFELD R: Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. Neuroimmunol. (2002) 123:188–192.
   PubMed Web of Science ®Google Scholar
• TEITELBAUM D, BRENNER T, ABRAMSKY 0, AHARONI R, SELA M, ARNON R: Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.Malt. Scler. (2003) 9:592–599.
   PubMed Web of Science ®Google Scholar
• SALAMA HH, HONG J, ZANG YC, EL-MONGUI A, ZHANG J: Blocking effects of serum reactive antibodies induced by glatiramer acetate in multiple sclerosis. Brain (2003) 126:2638–2647.
   PubMed Web of Science ®Google Scholar
• WOLINSKY JS, TOYKA KV, KAPPOS L, GROSSBERG SE: Interferon-beta antibodies: Implications for the treatment of MS. Lancet Neurol. (2003) 2:528.
   PubMed Web of Science ®Google Scholar
• BORNSTEIN MB, MILLER A,SLAGLE S et al.: A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New Engl.' Med. (1987) 317:408–414.
   Google Scholar
• JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial.aNeurology (1995) 45:1268–1276.
   PubMed Web of Science ®Google Scholar
• •Phase III pivotal trial that led to FDA-approval. Earliest data from the longest organised clinical trial of an immunomodulatory treatment for MS.
   Google Scholar
• JOHNSON KP, BROOKS BR,COHEN JA et al.: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology (1998) 50:701–708.
   Google Scholar
• JOHNSON KP, BROOKS BR, FORD CC et al.: Glatiramer acetate (Copaxone): Comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Malt. Scier. (2003) 9:585–591.
   PubMed Web of Science ®Google Scholar
• •Long-term benefits of GA on disability and relapse-rate reduction in RR MS.
   Google Scholar
• JOHNSON KP, BROOKS BR, FORD CC et al.: Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Malt. Scler. (2000) 6:255–266.
   PubMed Web of Science ®Google Scholar
• JOHNSON KP, BROOKS BB, FORD CC et al.: Results of the long-term (8-year) prospective open-label trial of glatiramer acetate for relapsing multiple sclerosis. Presented at the 54th Annual Meeting of the American Academy of Neurology Denver, USA (2002).
   Google Scholar
• WEINSHENKER BG: The natural historyof multiple sclerosis. Mult. Scler: (1995) 13:119–144.
   Google Scholar
• FORD C, JOHNSON K, BROOKS B et al.: Sustained efficacy and tolerability of glatiramer acetate in relapsing-remitting multiple sclerosis patients for over 10 years. Proceedings of the 1 gh Annual Meeting of the European Committee for Treatment and Research M Multiple Sclerosis (ECTRIMS). Milan, Italy (2003) Poster 485.
   Google Scholar
• BONES CHI FM, ROVARIS M, JOHNSON KP et al.: Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled trials. Malt. Scler. (2003) 9:349–355.
   PubMed Web of Science ®Google Scholar
• COMI G, FILIPPI M, WOLINSKY JS, and the EUROPEAN/CANADIAN GLATIRAMER ACETATE STUDY GROUP: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neurol (2001) 49:290–297.
   PubMed Web of Science ®Google Scholar
• WOLINSKYJS, JOHNSON KP, COMI G et al.: The effects of glatiramer acetate on sustained accumulated disability in relapsing multiple sclerosis are evidentwithin one year: Meta-analysis results of three double blind, placebo-controlled trials. Proceedings of the Igh Annual Meeting of the European Committee for Treatment and Research M Malt. Scler. (ECTRIMAMilan, Italy (2003) Poster 487.
   Google Scholar
• ROVARIS M, COMI G, ROCCA MA, WOLINSKY JS, FILIPPI M, and the EUROPEAN/CANADIANGLATIRAMER ACETATE STUDY GROUP: Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and its implications. Brain (2001) 124:1803–1812.
   PubMed Web of Science ®Google Scholar
• FILIPPI M, ROVARIS M, ROCCA MA et al.: Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology (2001) 57:731–733.
   PubMed Web of Science ®Google Scholar
• •The first study to show GA reduced the number of new MRI lesions that evolved into persistent Ti hypointense lesions ('black holes).
   Google Scholar
• KHAN 0, CHING W, CAON C et al: Combining immunomodulation and neuroprotection: Cerebral axonal recovery in relapsing-remitting multiple sclerosis patients treated with glatiramer acetate. Proceedings of the Igh Annual Meeting of the European Committee for Treatment and Research M Malt. Scler. (ECTRIMAMilan, Italy (2003) Poster 268.
   Google Scholar
• MANCARDI GL, SARDANELLI F, PARODI RC et al.: Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology (1998) 50:1127–1133.
   PubMed Web of Science ®Google Scholar
• GE Y, GROSSMAN RI, UDUPA JK et al: Glatiramer acetate (Copaxone) treatment in relapsing-remitting quantitative MRI assessment. Neurology (2000) 54:813–817.
   PubMed Web of Science ®Google Scholar
• WOLINSKY JS, NARAYANA PA, JOHNSON KP, and the COPOLYMER 1 MULTIPLE SCLEROSIS STUDY GROUP: Unites States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Malt. Scier. (2001) 7:33–41.
   PubMed Web of Science ®Google Scholar
• WOLINSKY JS, COMI G, FILIPPI M et al.: Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology (2002) 59:1284–1286.
   PubMed Web of Science ®Google Scholar
• CARRA A, ONAHA P, SINAY V et al.: A retrospective observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur. Neurol (2003) 10:671–676.
   Web of Science ®Google Scholar
• KHAN OA, TSELIS AC, KAMHOLZ JA, GARBERN JY, LEWIS RA, LISAK RP: A prospective, open-label treatment trial to compare the effect of IFNI3-1a (Avonex), IFNI3- lb (Betaseron), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis. Eur: Neurol (2001) 8:141–148.
   Web of Science ®Google Scholar
• KHAN OA, TSELIS AC, KAMHOLZ JA, GARBERN JY, LEWIS RA, LISAK RP: A prospective, open-label treatment trial to compare the effect of IFNI3-1a (Avonex), IFNI3- lb (Betaseron), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy.Malt. Scler: (2001) 7:349–353.
   Google Scholar
• FLECHTER S, VARDI J, POLLAK L, RABEL JM: Comparison of glatiramer acetate (Copaxone®) and interferon 13-1b (Betaferon®) in multiple sclerosis patients: an open-label 2-year follow-up. J. Neurol Sci. (2002) 197:51–55.
   PubMed Web of Science ®Google Scholar
• •Open-label study comparing the efficacy of GA as switch therapy from an IFN-I3.
   Google Scholar
• FLECHTER S, KOTT E, STEINER-BIRMANNS B, NISIPEANU P, KORCZYN AD: Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.Clio. Neuropharmacol (2002) 25:11–15.
   PubMed Web of Science ®Google Scholar
• HAAS J: Onset of clinical benefit of glatiramer (Copaxone) acetate in 255 patients with relapsing-remitting multiple sclerosis. Proceedings of the 55th Annual Meeting of the American Academy of Neurology Honolulu, USA (2003) P06.105.
   Google Scholar
• BENSON K, HARTZ AJ: A comparison of observational studies in randomized, controlled studies. N Engl. J. Med. (2000) 342:1878–1886.
   PubMed Web of Science ®Google Scholar
• KHAN 0, CAON C, ZVARTAU-HIND M, DIN MU, LISAK RP: Clinical course before and after change of immunomodulating therapy in relapsing remitting MS. Proceedings of the 5.7d Annual Meeting of the American Academy of Neurology Philadelphia, USA (2001) P05.104.
   Google Scholar
• CAON C, CHING W, DIN M, ZVARTAU-HIND M, LISAK R,KHAN 0: Extended follow-up and clinical course after change of immunomodulatory therapy in relapsing-remitting MS. Proceedings of the LP Annual Meeting of the European Neurological Society Istanbul, Turkey (2003).
   Google Scholar
• ZWIBEL H, for the COPAXONE TREATMENT IND STUDY GROUP: Benefit of Copaxone demonstrated in patients with relapsing-remitting multiple sclerosis (RRIVIS) previously treated with interferon. Proceedings of the 11th Annual Meeting of the European Neurological Socieh,. Paris, France (2001) Poster 521.
   Google Scholar
• DHIB-JALBUT S: Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology (2002) 58\(Suppl. 4):S3–S9.
   Google Scholar
• SIMPSON D, NOBLE S, PERRY C: Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs (2002) 16:825–850.
   PubMed Web of Science ®Google Scholar
• MILO R, PANITCH H: Additive effects of copolymer-1 and interferon beta-lb on the immune response to myelin basic protein. Neuroimmunol (1995) 61:185–193.
   PubMed Web of Science ®Google Scholar
• LUBLIN F, BAIER M, CUTTER G et al.: Results of the extension of the trial to assess the longer term safety of combining interferon beta-la and glatiramer acetate. Neurology (2002) 58(S3):A85.
   PubMed Web of Science ®Google Scholar
• DHIB-JALBUT S, CHEN M, HENSCHEL K, FORD D,COSTELLO K, PANITCH H: Effect of combined IFN113- la and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Malt. Stier: (2002) 8:485–491.
   Google Scholar
• AHARONI R, MESHORER A, SELA M, ARNON R: Oral treatment of mice with copolymer 1 (glatiramer acetate) results inthe accumulation of specific Th2 cells in the central nervous system. J. Neuroimmuna (2002) 126:58–68.
   PubMed Web of Science ®Google Scholar
• MARON R, SLAVIN AJ, HOFFMANN E, KOMAGATA Y, WEINER HL: Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: Cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines.Int. Immunol. (2002) 14:131–138.
   PubMed Web of Science ®Google Scholar
• WOLINSKY JS, PROMISE STUDY GROUP: The diagnosis of primary progressive multiple sclerosis. .1. Nemo]. Sci. (2003) 206:145–152.
   Google Scholar
• FUSCO C, ANDREONE V,COPPOLA G et al: HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology(2001) 57: 1976-1979.
   Google Scholar
• FARINA C, WAGENPFEIL S, HOHLFELD R: Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis: A pilot study.' Neurol (2002) 249:1587–1592.
   PubMed Web of Science ®Google Scholar
• KORNEK B, BERNERT G, BALASSY C, GELDNERJ, PRAYER D, FEUCHT M: Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics (2003) 34:120–126.
   PubMed Web of Science ®Google Scholar
• MANCARDI GL, MURIALDO A, DRAGO F et al: Localized lipoatrophy after prolonged treatment with copolymer 1. Neurol (2000) 247:220–221.
   Web of Science ®Google Scholar
• HWANG L, ORENGO I: Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis. Cutts (2001) 68:287–288.
   PubMed Web of Science ®Google Scholar
• COYLE PK, JOHNSON KP, PARDO L,STARK Y: Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Proceedings of the Igh Annual Meeting of the European Committee for Treatment and Research M Malt. Scler. (ECTRIMS), Milan, Italy (2003) Poster 268.
   Google Scholar
• ZIEMMSEN T, NEUHAUS 0,HOHLFELD R: Risk-benefit assessment ofglatiramer acetate in multiple sclerosis. Drug Sal (2001) 24(13):979–990.
   PubMed Web of Science ®Google Scholar
• http://www.nationalmssociety.org/ Sourcebook-Early.asp NATIONAL MULTIPLE SCLEROSIS SOCIETY: National Multiple Sclerosis Society Information Sourcebook. Last updated, April (2003).
   Google Scholar